Literature DB >> 15242722

Sulfonamide hypersensitivity.

Christopher G Slatore1, Stephen A Tilles.   

Abstract

Sulfonamide antibiotics can result in a wide variety of hypersensitivity reactions. No validated diagnostic tests are available for sulfonamide reactions; therefore, clinicians must rely on the combination of a careful patient history, review of medical records, and a sound knowledge base regarding the common clinical manifestations of sulfonamide hypersensitivity reactions. Although HIV-infected individuals have a high risk for hypersensitivity reactions to sulfamethoxazole, readministering the drug can usually be performed safely by using a desensitization protocol. Sulfonamide-containing medications that are not antibiotics also have the capacity for causing hypersensitivity reactions. Whether the sulfa moiety confers a risk of cross-reaction is controversial. The preponderance of available evidence suggests that sulfonamide antibiotics probably do not cross-react with sulfonamide nonantibiotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242722     DOI: 10.1016/j.iac.2004.03.011

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  19 in total

Review 1.  Non-steroidal drug-induced glaucoma.

Authors:  M R Razeghinejad; M J Pro; L J Katz
Journal:  Eye (Lond)       Date:  2011-06-03       Impact factor: 3.775

2.  Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine.

Authors:  Jennifer Buur; Ronald Baynes; Geof Smith; Jim Riviere
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Approach to managing patients with sulfa allergy: use of antibiotic and nonantibiotic sulfonamides.

Authors:  David Ponka
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

4.  Antibacterial activities of sulfamethoxazolyl-azo-phenols and their Cu(II) complexes along with molecular docking properties.

Authors:  Nilima Sahu; Sudipa Mondal; Nayim Sepay; Suvroma Gupta; Elena Torres-Lopez; Shinnosuke Tanaka; Takashiro Akitsu; Chittaranjan Sinha
Journal:  J Biol Inorg Chem       Date:  2017-04-28       Impact factor: 3.358

5.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

6.  The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.

Authors:  Jin Ku Kang; Jae Sam Hwang; Hyo Jung Nam; Keun Jae Ahn; Heon Seok; Sung-Kuk Kim; Eun Young Yun; Charalabos Pothoulakis; John Thomas Lamont; Ho Kim
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

7.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

Review 8.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

9.  Polyamine transport as a target for treatment of Pneumocystis pneumonia.

Authors:  Chung-Ping Liao; Otto Phanstiel; Mark E Lasbury; Chen Zhang; Shoujin Shao; Pamela J Durant; Bi-Hua Cheng; Chao-Hung Lee
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

10.  All-trans retinoic acid in combination with primaquine clears pneumocystis infection.

Authors:  Guang-Sheng Lei; Chen Zhang; Shoujin Shao; Hsin-Wei Jung; Pamela J Durant; Chao-Hung Lee
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.